53261-25-9

Basic information

• Product Name: diamminedichlorodihydroxyplatinum IV
• Synonyms: diamminedichlorodihydroxyplatinum IV
• CAS NO: 53261-25-9
• Molecular Formula: Cl₂H₈N₂O₂Pt
• Molecular Weight: 330.03
• Mol File: 53261-25-9.mol
• Article Data: 67

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 5990mmHg at 25°C
• CAS DataBase Reference: diamminedichlorodihydroxyplatinum IV(CAS DataBase Reference)
• NIST Chemistry Reference: diamminedichlorodihydroxyplatinum IV(53261-25-9)
• EPA Substance Registry System: diamminedichlorodihydroxyplatinum IV(53261-25-9)

Safety Data

• Hazardous Substances Data: 53261-25-9(Hazardous Substances Data)

Usage

InChI:InChI=1/2ClH.2H3N.2H2O.Pt/h2*1H;2*1H3;2*1H2;/q;;;;;;+4/p-4

Upstream product

• 26035-31-4 cisplatine 
• 7722-84-1 dihydrogen peroxide 
• 15663-27-1 cisplatin 
• 7732-18-5 water 
• 26035-31-4 transplatin 
• 7722-64-7 potassium permanganate 

Downstream Products

• 16893-05-3 cis-diaammineplatinum(IV) tetrachloride 
• 15663-27-1 cisplatin 
• 1613703-75-5 C₃₈H₃₆Cl₄N₄O₈Pt 

Relevant articles and documents

Tetravalent platinum complex containing BET inhibitor and application

The invention discloses a tetravalent platinum complex containing a BET inhibitor. The structure of the tetravalent platinum complex is as shown in a general formula I, wherein substituent groups are defined in the specification. The advantages of the tetravalent platinum complex are utilized, and the synergistic anti-tumor effect of the BET inhibitor and cis-platinum is exerted. The tetravalent platinum complex containing the BET inhibitor shows broad-spectrum and excellent in-vitro anti-tumor activity, the activity of the tetravalent platinum complex is obviously superior to that of cis-platinum, the BET inhibitor and the mixture of the cis-platinum and the BET inhibitor according to the ratio of 1: 1, and the tetravalent platinum complex has huge potential of being developed into a novel broad-spectrum anti-tumor drug.

Berberine coupled cis-platinum compound as well as preparation method and application thereof

The invention relates to the technical field of pharmaceutical chemicals, and in particular, relates to a berberine coupled cis-platinum compound as well as a preparation method and application thereof. The invention provides a berberine coupled cis-platinum compound. The berberine coupled cis-platinum compound has a structure represented by a formula I in the specification. Results of the embodiment show that the berberine coupled cis-platinum compound provided by the invention can effectively inhibit the proliferation activity of intestinal cancer cells and significantly reduce the killing ability of cis-platinum to normal intestinal epithelial cells, and in-vivo experiments of mice prove that the berberine coupled cis-platinum compound has a better tumor inhibition effect than cis-platinum.

Tetravalent veratric acid platinum as well as preparation method and application thereof

The invention belongs to the technical field of medicine, and particularly relates to tetravalent veratric acid platinum as well as a preparation method and application thereof, the structural formula of the tetravalent veratric acid platinum is shown in the specification, and the preparation method comprises the following steps: (1) synthesizing hydroxyl platinum; (2) synthesizing tetravalent platinum veratryl acid; and (3) purifying tetravalent platinum veratryl acid. The tetravalent veratric acid platinum provided by the invention belongs to a tetravalent platinum prodrug, is a novel efficient anti-tumor active compound, has a broad-spectrum anti-cancer effect, is small in killing effect on normal cells of a human body, is efficient and low in toxicity, has a relatively high medicinal value, and is simple in preparation method, low in cost and easy for industrial production.